These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 27158673)
1. Acute administration of ivacaftor to people with cystic fibrosis and a Adam RJ; Hisert KB; Dodd JD; Grogan B; Launspach JL; Barnes JK; Gallagher CG; Sieren JP; Gross TJ; Fischer AJ; Cavanaugh JE; Hoffman EA; Singh PK; Welsh MJ; McKone EF; Stoltz DA JCI Insight; 2016 Apr; 1(4):e86183. PubMed ID: 27158673 [TBL] [Abstract][Full Text] [Related]
2. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
3. Cystic Fibrosis Transmembrane Conductance Regulator in Sarcoplasmic Reticulum of Airway Smooth Muscle. Implications for Airway Contractility. Cook DP; Rector MV; Bouzek DC; Michalski AS; Gansemer ND; Reznikov LR; Li X; Stroik MR; Ostedgaard LS; Abou Alaiwa MH; Thompson MA; Prakash YS; Krishnan R; Meyerholz DK; Seow CY; Stoltz DA Am J Respir Crit Care Med; 2016 Feb; 193(4):417-26. PubMed ID: 26488271 [TBL] [Abstract][Full Text] [Related]
4. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269 [TBL] [Abstract][Full Text] [Related]
5. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666 [TBL] [Abstract][Full Text] [Related]
6. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
7. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy. Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004 [TBL] [Abstract][Full Text] [Related]
8. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T. Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453 [TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001 [TBL] [Abstract][Full Text] [Related]
10. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599 [TBL] [Abstract][Full Text] [Related]
11. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
12. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation. Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054 [TBL] [Abstract][Full Text] [Related]
14. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA Chest; 2013 Jan; 143(1):14-18. PubMed ID: 23276841 [TBL] [Abstract][Full Text] [Related]
15. Characterization of cystic fibrosis airway smooth muscle cell proliferative and contractile activities. Jang JH; Panariti A; O'Sullivan MJ; Pyrch M; Wong C; Lauzon AM; Martin JG Am J Physiol Lung Cell Mol Physiol; 2019 Nov; 317(5):L690-L701. PubMed ID: 31508974 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC; Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620 [TBL] [Abstract][Full Text] [Related]
18. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833 [TBL] [Abstract][Full Text] [Related]
19. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States. Taylor-Cousar J; Niknian M; Gilmartin G; Pilewski JM; J Cyst Fibros; 2016 Jan; 15(1):116-22. PubMed ID: 25682022 [TBL] [Abstract][Full Text] [Related]
20. Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation. Yousef S; Solomon GM; Brody A; Rowe SM; Colin AA Chest; 2015 Mar; 147(3):e79-e82. PubMed ID: 25732475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]